AIVITA Biomedical Named 2026 Prix Galien USA Nominee for Personalized Immunotherapy Platform
核心洞察
AIVITA Biomedical (搜索), Inc. has been named a 2026 Prix Galien USA nominee in the "Best Startup" category, recognizing its personalized immunotherapy platform.
The company's autologous dendritic-cell platform uses a patient's own tumor-initiating cells (搜索) to train the immune system against the full repertoire of cancer-specific antigens.
The pan-antigenic approach is advancing in investigational clinical programs for glioblastoma (搜索), melanoma (搜索), and other solid tumors, with reported tumor eradication and prolonged progression-free survival.
AIVITA Biomedical (搜索), Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, has been named a 2026 Prix Galien USA nominee in the "Best Startup" category. The announcement was made on August 13, 2026, from the company's headquarters in Irvine, California. The Prix Galien USA Awards, presented by The Galien Foundation, recognize exceptional scientific innovation with the potential to improve human health and are widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
"We are honored to be recognized by The Galien Foundation among an exceptional group of innovators," said AIVITA CEO Dr. Hans S. Keirstead. "This nomination reflects the dedication of our team and the potential of our personalized dendritic-cell platform to address urgent unmet needs in cancer and infectious disease. Our goal is to make advanced, patient-specific immunotherapies practical, scalable and accessible to patients around the world."
Nominees for this year's "Best Startup" category were selected following rigorous review. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.
A Pan-Antigenic Dendritic-Cell Platform
AIVITA's proprietary autologous dendritic-cell platform is designed to use antigens derived from a patient's own tumor-initiating cells (搜索), which drive cancer, to train the patient's immune system against the full repertoire of antigens specific to that individual's cancer. This pan-antigenic approach is being advanced in investigational clinical programs in glioblastoma (搜索), melanoma (搜索), and other solid tumors.
According to the company, its patient-specific cancer treatments have shown promise, including eradicating tumors without harmful side effects in melanoma (搜索) and renal cell cancer (搜索), and prolonging progression-free survival in glioblastoma (搜索). The cancer immunotherapy targets the "seed of all cancers," tumor-initiating cells (搜索), with a unique pan-antigenic approach that targets all neoantigens specific to the patient's cancer.
The Clean Super Vaccine Platform
The same technology underpins AIVITA's Clean Super Vaccine platform, a personalized multi-pathogen vaccine kit designed to combine a patient's own antigen-presenting cells with recombinant antigens from multiple pathogens. The platform has been evaluated clinically in COVID-19 (搜索) and is being advanced for broader use in infectious disease preparedness, with an emphasis on point-of-care production and global accessibility.
The multi-pathogen vaccine kit for infectious diseases is targeted to emerging nations, enabling point-of-care vaccine production in minimally equipped facilities by minimally trained third-party technicians.
Company Background and Recognition
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical (搜索) utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient, and economical manufacturing systems that support its therapeutic pipeline.
"The Prix Galien USA Awards celebrate innovations that can reshape medical practice and improve lives," added Dr. Keirstead. "We are proud that AIVITA's approach to precision immunology has been recognized as part of that important mission."
The Galien Foundation, established in Paris in 1970, honors the collaborative, multidisciplinary progress that defines modern biopharmaceutical innovation. The 2026 Prix Galien USA Awards mark 20 years of recognizing breakthroughs in medical technology, digital health, and entrepreneurship.